Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Humacyte (NASDAQ:HUMA) released its quarterly earnings results on Friday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07, Zacks reports.

Humacyte Stock Down 2.5 %

Shares of Humacyte stock opened at $1.96 on Friday. The business has a fifty day simple moving average of $3.61 and a 200 day simple moving average of $4.51. The stock has a market cap of $246.68 million, a PE ratio of -1.46 and a beta of 1.36. Humacyte has a 12 month low of $1.76 and a 12 month high of $9.97.

Analysts Set New Price Targets

A number of research analysts have commented on HUMA shares. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Wednesday. Benchmark reiterated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.